Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Advanz Sees Mumbai Center As Strategic Strength

Using its Indian back-office function to realize synergies from acquired sales and marketing assets in western Europe forms a key part of Advanz Pharma’s growth strategy.

Business Strategies M & A

Consensus Is Essential To Find Best Value-Added Path

Finding a consensus across European stakeholders on how best to recognize and reward the benefits of value added medicines is key to the sector’s success, says Arun Narayan – chairman of the value added medicines sector group at Medicines for Europe and also head of global portfolio strategy and head of European business operations at Mylan – in an exclusive interview with Generics Bulletin.

Value-Added Medicines Regulation

Rovi Is Weeks From Long-Acting Risperidone Filing

Rovi hopes by the end of this year to file a hybrid marketing authorization application in Europe for a once-a-month sustained-release injectable formulation of risperidone. A US filing is scheduled for the first half of next year.

Value-Added Medicines Neurology

European Industry Sets Out Value Added Medicines Priorities

Incentives for innovation around known molecules and new guidelines for value added medicines are needed, Medicines for Europe has insisted at the organization’s value added medicines conference in Brussels yesterday. The European off-patent industry association has called for a “pragmatic value framework” to recognize value added medicines, as well as welcoming the advent of digital health solutions.

Value-Added Medicines Regulation

Amneal Starts Seeking International Partners

In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.

Business Strategies China

Accord Strikes Thiotepa Deal With Adienne

Accord Healthcare has secured commercial rights to Adienne’s novel lyophilized formulation of thiotepa in Europe, extending its portfolio of cancer treatments.

Value-Added Medicines Cancer
See All
UsernamePublicRestriction

Register